Value for Pharmaceutical Companies
In clinical development, Nodality can provide key information at critical decision points including:
- Dose and schedule selection: Measuring the functional status of pathways downstream of the target at various time points to determine the extent of biological coverage and specify dose response curves.
- Patient selection: Discovering unique signaling signatures to identify patients that are most likely to respond to specific therapeutics.
- Indication selection: Identifying specific drug activities in discrete cell subtypes and comparing those against cellular dysregulation in different diseases, Nodality can enable optimal indication selection of candidate compounds.
- Combination therapy selection: Determining signaling signatures in specific cellular pathways, Nodality can predict which drug combinations will be necessary to act on critical networks.
Through its clinical test development and validation, Nodality has demonstrated that Single Cell Network Profiling (SCNP) can provide highly reproducible results meeting regulatory requirements for clinical use. SCNP analyses in immunology, autoimmune disorders, and oncology demonstrate the broad applicability of SCNP to multiple diseases and indications.
Nodality recommends that partners collect samples according to a standard cryopreservation procedure (PDF: 971K) which Nodality has determined to be optimal for SCNP. If you have any questions about this protocol or any of the global facilities that Nodality has qualified to perform this protocol for SCNP, please contact us.
